nicardipine has been researched along with Carcinoma, Squamous Cell in 2 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Esophageal achalasia (EA) is a rare disease in man and animals and there are many discussions on its higher risk of esophageal cancer." | 5.30 | High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice. ( Baskar, R; Fukuda, K; Hongyo, T; Kurooka, M; Li, LY; Matsuda, H; Miyata, M; Nakajima, H; Nomura, T; Sutoh, K, 1998) |
| "Esophageal achalasia (EA) is a rare disease in man and animals and there are many discussions on its higher risk of esophageal cancer." | 1.30 | High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice. ( Baskar, R; Fukuda, K; Hongyo, T; Kurooka, M; Li, LY; Matsuda, H; Miyata, M; Nakajima, H; Nomura, T; Sutoh, K, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akazawa, S | 1 |
| Honda, T | 1 |
| Sampi, K | 1 |
| Futatsuki, K | 1 |
| Kurooka, M | 1 |
| Hongyo, T | 1 |
| Nakajima, H | 1 |
| Baskar, R | 1 |
| Li, LY | 1 |
| Fukuda, K | 1 |
| Sutoh, K | 1 |
| Miyata, M | 1 |
| Matsuda, H | 1 |
| Nomura, T | 1 |
2 other studies available for nicardipine and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
[Combination chemotherapy of nicardipine and vindesine sulfate, cis-diammine dichloroplatinum (II) for patients with advanced esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Squamous Cell; | 1984 |
High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Carcinogens; Carcinoma, Squamous Cell; Esop | 1998 |